The influence of D-chiro-inositol and D-myo-inositol in pregnant women with glucose intolerance

Dell'Edera, Domenico; Sarlo, Francesca; Allegretti, Arianna; Simone, F.; Lupo, Maria Giovanna; Epifania, Annunziata Anna

doi:10.3892/br.2017.939

Cited by 18 publications

(28 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As already mentioned, Celentano et al recently demonstrated the greatest benefit of Myo (4000 mg) compared with DCI alone (500 mg) and Myo/DCI association (1100 mg/27.6 mg) in the prevention of GDM in high‐risk pregnant women. These results, at odds with the previous study by Dell'Edera et al, could be due to either the use of inadequate doses of Myo/DCI or to late intervention …”

Section: Clinical Effects Of Myo/dci Association Supplementationcontrasting

confidence: 75%

“…However, these dosages are not currently allowed for supplementation. Furthermore, no side effects were observed in patients receiving intervention with DCI (27.5 up 500 mg/day) in the clinical studies available …”

Section: Inositol Safetymentioning

confidence: 92%

“…When pregnant women with fasting blood glucose less than 92 mg/dl in the first trimester were randomized in the study by Dell'Edera et al to intake either only folic acid (400 mg/die) or a fixed‐dosage combination of Myo/DCI (1750 mg/250 mg/die plus zinc, methylsulfonylmethane, and 5‐methyltetrahydrofolic acid), the incidence of GDM at 24 weeks of pregnancy was significantly greater only in the FA group (relative risk, RR = 3.35; 95% confidence interval, CI, 1.37‐8.17; P = .0028). Moreover, birthweight was significantly lower in the Myo/DCI group (RR = 5.12; 95% CI, 1.21‐21.68; P = .0099).…”

Section: Clinical Effects Of Myo/dci Association Supplementationmentioning

confidence: 99%

See 2 more Smart Citations

Inositol and antioxidant supplementation: Safety and efficacy in pregnancy

Formoso

Baldassarre

Ginestra

et al. 2019

Diabetes Metabolism Res

View full text Add to dashboard Cite

Summary Pregnancies complicated by diabetes have largely increased in number over the last 50 years. Pregnancy is characterized by a physiologic increase in insulin resistance, which, associated with increased oxidative stress and inflammations, could induce alterations of glucose metabolism and diabetes. If not optimally controlled, these conditions have a negative impact on maternal and foetal outcomes. To date, one can resort only to diet and lifestyle to treat obesity and insulin resistance during pregnancy, and insulin remains the only therapeutic option to manage diabetes during pregnancy. However, in the last years, in a variety of experimental models, inositol and antioxidants supplementation have shown insulin‐sensitizing, anti‐inflammatory, and antioxidant properties, which could be mediated by some possible complementary mechanism of action. Different isomers and multiple combinations of these compounds are presently available: Aim of the present review article is to examine the existing evidence in order to clarify and/or define the effects of different inositol‐ and antioxidant‐based supplements during pregnancy complicated by insulin resistance and/or by diabetes. This could help the clinician's evaluation and choice of the appropriate supplementation regimen.

show abstract

Section: Clinical Effects Of Myo/dci Association Supplementationcontrasting

confidence: 75%

Section: Inositol Safetymentioning

confidence: 92%

Section: Clinical Effects Of Myo/dci Association Supplementationmentioning

confidence: 99%

See 1 more Smart Citation

Inositol and antioxidant supplementation: Safety and efficacy in pregnancy

Formoso

Baldassarre

Ginestra

et al. 2019

Diabetes Metabolism Res

View full text Add to dashboard Cite

show abstract

“…In the first group, the best results were obtained for the improvement of the glucose profile, total cholesterol, LDL, and TG [59]. This was recently confirmed by Dell’ Edera et al [60] administering all pregnant women in the first trimester of pregnancy with fasting plasma glucose >92 mg/dL a supplement consisting of DCI 250 mg, MI 1.75 g, zinc 12.5 mg, methylsulfonylmethane 10 mg, and 5-methyltetrahydrofolic acid 400 μg daily, compared to the group received only folic acid 400 μg. More than 3-fold lower exposure of treated women to gestational diabetes, fetal macrosomia was found, but no differences in preterm delivery rate and neonatal hypoglycaemia [60].…”

Section: Cyclitols Insulin Resistance and Diabetesmentioning

confidence: 80%

The Healing-Promoting Properties of Selected Cyclitols—A Review

et al. 2018

View full text Add to dashboard Cite

Introduction: Myo-inositol and its derivatives cyclitols play an important role in the processes of cell regulation, signal transduction, osmoregulation, and ion channel physiology, and are a component of the cell membrane. Free cyclitols present in food or released during the degradation of galactosyl cyclitols by bacteria (in digestive tract) show some physiological benefits. Aim: The aim of this paper is to present and analyze the documented data about curative and healing properties of cyclitols. Results and discussion: Cyclitols are well known compounds in the treatment of an accompanied diabetes insulin resistance, and also obesity and polycystic ovarian syndrome. d-chiro-Inositol deficiency exacerbates insulin resistance in the liver, muscles, and fat, while depletion of myo-inositol results in the development of diabetic complications. Cyclitols are successfully applied in treatment of polycystic ovarian syndrome, simultaneous are observed effective reducing of BMI, improving the hormonal profile, and increasing fertility. Moreover, cyclitols have anti-atherogenic, anti-oxidative, anti-inflammatory, and anti-cancer properties. Conclusion: The properties of cyclitols may be a good therapeutic option in the reduction of metabolically induced inflammation. Due to well drugs tolerance and low toxicity of these compounds, cyclitols are recommend for pregnant women and also for children. Another advantage is their widespread presence and easy availability, which encourages their use in medicine.

show abstract

“…A recent study conducted by Dell’Edera at al [ 40 ]. demonstrated that the supplementation with D-chiro-inositol and D-myo-inositol allows a better control of maternal glycemia resulting in a lower incidence of GDM ( P = 0.0028) and more favorable perinatal outcomes referring to the risk of macrosomia ( P = 0.0099).…”

Section: Discussionmentioning

confidence: 99%

Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: study protocol for a randomized controlled trial

Asimakopoulos

Pergialiotis

Anastasiou

et al. 2020

Trials

View full text Add to dashboard Cite

Background Gestational diabetes mellitus (GDM) is defined as impaired glucose tolerance with onset or first recognition during pregnancy, which is characterized by an increased insulin resistance. Gestational diabetes mellitus is associated with pregnancy-related maternal and fetal morbidity (both antenatal and perinatal). Myo-inositol has been suggested to improve insulin resistance in women with polycystic ovary syndrome. The aim of this study is to examine the impact of myo-inositol supplementation during pregnancy on the incidence of gestational diabetes mellitus. Methods We will conduct a single-center, open-label, randomized controlled trial. A total of 160 healthy pregnant women with singleton pregnancy at 11–13 +6 weeks of gestation will be randomly allocated in two groups: intervention group ( N = 80) and control group ( N = 80). The intervention group will receive myo-inositol and folic acid (4000 mg myo-inositol and 400 mcg folic acid daily) from 11 to 13 +6 weeks of gestation until 26–28 weeks of gestation, while the control group will receive folic acid alone (400 mcg folic acid daily) for the same period of time as intervention group. The primary outcome will be gestational diabetes incidence rate at 26–28 weeks of gestation, according to the results of a 75 g oral glucose tolerance test held at 26–28 weeks of gestation. The secondary outcomes will include fasting blood glucose levels, glycated hemoglobin levels, insulin resistance level (evaluated by homeostasis model assessment of insulin resistance and Matsuda Index), and incidence rate of diet-treated gestational diabetes and diabetes requiring insulin therapy at 26–28 weeks of gestation. Discussion This trial will provide evidence for the effectiveness of myo-inositol supplementation during pregnancy in reducing the incidence of gestational diabetes mellitus. Trial registration ISRCTN registry: ISRCTN16142533 . Registered on 9 March 2017.

show abstract

The influence of D-chiro-inositol and D-myo-inositol in pregnant women with glucose intolerance

Cited by 18 publications

References 18 publications

Inositol and antioxidant supplementation: Safety and efficacy in pregnancy

Inositol and antioxidant supplementation: Safety and efficacy in pregnancy

The Healing-Promoting Properties of Selected Cyclitols—A Review

Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: study protocol for a randomized controlled trial

Contact Info

Product

Resources

About